Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLCneoSCORE ⅡA Prospective, Randomized, Open-Label, Multi-Center Phase 3 Trial

Next Previous
Trial Profile

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLCneoSCORE ⅡA Prospective, Randomized, Open-Label, Multi-Center Phase 3 Trial

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms neoSCORE II

Most Recent Events

  • 13 Dec 2022 Planned number of patients changed from 236 to 250.
  • 20 Nov 2022 Status changed from not yet recruiting to recruiting.
  • 20 Nov 2022 Planned End Date changed from 1 May 2029 to 11 Nov 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top